Acute interstitial nephritis due to Ciclosporin a toxicity during Behçet’s disease

Salem Bouomrani1-2*, Nesrine Regaïeg1, Marwa Nefoussi1 and Safa Trabelsi1

1Department of Internal medicine. Military Hospital of Gabes. Gabes 6000, Tunisia
2Sfax Faculty of Medicine. University of Sfax. Sfax 3029, Tunisia

Abstract

Introduction: Ciclosporin A is an immunosuppressive molecule widely used in Behçet’s disease (BD), especially for severe ocular and/or neurological disorders. Its particular toxicity in this field has, however, largely limited its use during this vasculitis. We report an aspect.

Case report: 26-year-old patient followed since the age of 20 for BD with severe ocular involvement (bilateral posterior steroid-resistant uveitis with a significant decrease in visual acuity) requiring treatment with Ciclosporin A at a dose of 5mg/kg/twice daily during the first month and then 5mg/kg/day as a maintenance dose to control uveitis. The one-year control report noted a creatinine at 147μmol/l with aseptic leucocyturia at 400 elements/l. Blood pressure was normal and there was no associated hematuria or proteinuria. The infectious and toxic investigation was normal. The ultrasound showed two kidneys of normal size and echo-structure. Renal biopsy revealed acute interstitial nephritis with images of toxic tubular necrosis. Cyclosporine was discontinued and replaced with azathioprine. Renal function normalized three weeks after stopping the molecule.

Conclusion: periodic and regular monitoring of renal function (blood and urine tests) is strongly recommended in order to detect renal damage early in the BD; especially if Ciclosporin A treatment.

*Correspondence to: Salem Bouomrani, MD, PhD, Department of Internal medicine, Military Hospital of Gabes. Gabes 6000. Tunisia, Tel: +00216 98977555; E-mail: salembouomrani@yahoo.fr

Key words: Behçet’s disease, cyclosporine A, interstitial nephritis, nephrotoxicity, side effect

Received: February 07, 2019; Accepted: February 11, 2019; Published: February 15, 2019
Discussion

The specific renal involvement of BD is exceptional [7,8]. In the large series, its frequency is estimated between 1.23% [9] and 2.6% [10], but often conditions the prognosis of the disease [7-11]. The clinical spectrum of this nephropathy may include microscopic hematuria, proteinuria, nephrotic syndrome, arterial hypertension, and acute or chronic renal failure [7-11].

Histologically, nephropathy during BD may be secondary amyloidosis, proliferative glomerulonephritis, mesangial nephropathy, extracapillary glomerulonephritis with crescents, focal segmental glomerulosclerosis and hyalinosis, thrombotic microangiopathy, or linear IgA nephropathy [7-13].

Ciclosporin A is an immunosuppressive molecule widely used during BD, especially if associated ocular and/or neurological involvement [4-6]; however, this molecule is not without risk, particularly demonstrated increased neurotoxicity [5] and nephrotoxicity [6] in patients with BD. Indeed, in the literature review by Akpolat T et al., five of the 23 patients with BD who developed renal impairment with renal failure had already received treatment with ciclosporin A [14]. Similarly, 45% of Sajjadi H, et al., patients with BD treated with low doses of cyclosporine A had elevations of serum creatinine [4].

As for histologically proven acute tubule-interstitial nephritis, it has only been reported once in BD [7].

This observation draws attention to the nephrotoxicity of Ciclosporin A in BD, which does not appear to be dependent on the duration of treatment or the total dose received [6].

Thus, regular clinical and biological renal monitoring is required in any patient followed for BD and receiving ciclosporin A therapy. In-time detection allows the recovery of renal function following decay and stopping this immunosuppressant [4].

Conclusion

As rare as it may be, this particular renal complication of cyclosporine A treatment in BD must be known by clinicians managing this disease.

Cyclosporine A treatment should be restricted to cases of BD refractory to any other immunosuppressive or immunomodulatory therapies. In these cases regular clinical and laboratory monitoring is strongly recommended in order to detect early abnormalities of renal function parameters.

References

1. Behçet H (1937) Über rezidivierende, aphthose, durch ein Virus verursachte Geschwüre am Munde, am Auge und an den Genitalien. Dermatologische Wochenschrift 36: 1152-1157.
2. Hell-Ulrich K (2014) [Vasculitis: New nomenclature of the Chapel Hill consensus conference 2012]. Z Rheumatol 73: 823-833. [Crossref]
3. Bouomrani S, Balli H, Béji M (2016) Anévrysmes pulmonaires bilatéraux à issue fatale au cours de la maladie de Behçet. Research fr 3: 1545.
4. Sajjadi H, Soheilian M, Ahmadieh H, Hassanein K, Parvin M, et al. (1994) Low dose cyclosporin-A therapy in Behçet’s disease. J Ocal Pharmacol 10: 553-560. [Crossref]
5. Bouomrani S, Hammami S, Braham R, Mahjoub S (2010) Ciclosporin-associated cerebral tumor-like location of Behçet’s disease. Rev Neurol (Paris) 166: 849-854.
6. Sarıcaoğlu H, Bulbul EB, Cikman ST, Dilek K, Tunali S (2004) Effects of long-term cyclosporine A therapy on renal functions in Behçet’s disease. Int J Tissue React 26: 93-96. [Crossref]
7. Zahiri K, Hachim K, Zamd A, Fatihi E, Benghanem MG, et al. (2003) Renal involvement in Behçet’s disease: review of 9 cases. Int J Rheum Dis 25: 2254-2260. [Crossref]
8. Redondo-Pachón MD, Enríquez R, Sirvent AE, Andrada E, Noguera-Pons R, et al. (2013) Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behçet’s disease. Nefrol Dial Transplant 28: 404-408. [Crossref]
9. Ounissi M, Ben Abdelghani K, Gargueh T, Turki S, Goucha R, et al. (2010) Renal involvement in Behçet’s disease. Tunis Med 88: 404-408. [Crossref]
10. Zheng W, Li G, Zhou M, Chen L, Tian X, et al. (2015) Renal involvement in Chinese patients with Behçet’s disease: a report of 16 cases. Int J Rheum Dis 18: 892-897. [Crossref]
11. Cho SB, Kim J, Kang SW, Yoo TH, Zheng Z, et al. (2013) Renal manifestations in 2007 Korean patients with Behçet’s disease. Yonsei Med J 54: 189-196. [Crossref]
12. Altay M, Secilmis S, Unverdi S, Ceri M, Duranay M (2012) Behçet’s disease and IgA nephropathy. Rheumatol Int 32: 2227-2229. [Crossref]
13. El Ramahi KM, Al Dalaan A, Al Shaikh A, Al Meshari K, Akhtar M (1998) Renal involvement in Behçet’s disease: review of 9 cases. J Rheumatol 25: 2254-2260. [Crossref]
14. Akpolat T, Dilek M, Akso K, Keser G, Toprak O, et al. (2008) Renal Behçet’s disease: an update. Semin Arthritis Rheum 38: 241-248. [Crossref]